China
Africa
Explore chapters and articles related to this topic
Therapeutic Nanostructures in Antitubercular Therapy
Published in Bhaskar Mazumder, Subhabrata Ray, Paulami Pal, Yashwant Pathak, Nanotechnology, 2019
Paulami Pal, Subhabrata Ray, Anup Kumar Das, Bhaskar Mazumder
Nanotechnology overcomes several lacunae in the conventional dosage forms. Developing a nanoparticle-based system and targeting it to the site of colonization of the microorganisms in the lungs will help to increase the efficacy of the dose regimen and will reduce the toxicity compared to the oral route through optimal drug utilization. Solid lipid nanoparticles (SLNs) combine the advantage of both polymeric nanoparticles and liposomes with the possibility of controlled drug release and drug targeting, increased drug stability, incorporation of both lipophilic and hydrophilic drugs, etc. The proposed approach for formulation development will not only help to combat the associated problems with these model antitubercular drugs, but also will result in better drug utilization at the site of infection.
Application of Nanomaterials in Food, Cosmetics, and Other Related Process Industries
Published in Vineet Kumar, Nandita Dasgupta, Shivendu Ranjan, Nanotoxicology, 2018
Adhena A. Werkneh, Eldon R. Rene, Piet N. L. Lens
Solid lipid nanoparticles (SLNs) are particles consisting of a “solid lipid shell matrix” (Dewan et al. 2015). In recent years, they have received the attention of researchers working in the fields of applied food and pharmaceutical sciences (Yin and Tsai 2015). SLNs have some distinct benefits for applications in the food industry. For foods and beverages that have low solubility in water and are unstable, SLNs have been used as a delivery system. For example, the presence of resveratrol in red wine and berries is beneficial to human health; however, it has limitations such as low oral bioavailability, short elimination half-life in the human body, and rapid metabolism. Such limitations can be resolved by the use of SNLs to improve/enhance photostability, bioactivity, and elimination half-life (Yin and Tsai 2015).
Nanocarrier-Mediated Therapeutic Protein Delivery
Published in Bhupinder Singh, Rodney J. Y. Ho, Jagat R. Kanwar, NanoBioMaterials, 2018
Akhlesh Kumar Jain, Teenu Sharma, Sunil Kumar Jain
Solid lipid nanoparticles (SLNs), prepared from solid lipids and stabilized using surfactants in an aqueous suspension, bear resemblance to nanoemulsions, except that liquid lipid in nanoemulsion is swapped with a solid lipid. However, controlled drug release can be attained in an outstanding manner by replacing a portion of solid lipids with oils, as solid lipids tend to lower the mobility of drug significantly (Martins et al., 2007). SLNs, of late, have emerged as an attractive carrier system for the delivery of protein/peptide (Marcato and Duran, 2008). SLNs offer various advantages over many other delivery vehicles, i.e. NPs, liposomes, ethosomes and lipid emulsions (Garcıa-Fuentes et al., 2003; Hou et al., 2003; Liu et al., 2008; Joshi and Muller, 2009) which include:
Cinnamaldehyde encapsulation within new natural wax-based nanoparticles; formation, optimization and characterization
Published in Journal of Dispersion Science and Technology, 2023
Atefe Shirvani, Sayed Amir Hossein Goli, Jaleh Varshosaz, Ali Sedaghat Doost
Solid lipid nanoparticles (SLNs) are colloidal systems of hard fats dispersed in an aqueous phase that can be appropriate for protection, encapsulation, and delivery systems of lipophilic bioactive materials. SLNs have some advantages of straightforward fabrication approach, potential for scaling-up at industrial level, excellent compatibility with other ingredients, high affinity to lipophilic bioactive compounds due to its hydrophobic nature. This high hydrophobicity leads to an exceptional encapsulation efficiency and slow release profile during application.[1–3] Solid lipid nanoparticles could be produced by wide range of fats, including relatively high-melting temperature fatty acids and triglycerides. Eltayeb et al.[4] used stearic acid to encapsulate ethylvanillin by electrospinning technique. They obtained SLNs with 60–70 nm and an encapsulation efficiency of 70%. The production of cocoa butter and hydrogenated coconut oil SLNs was evaluated by Salvia-Trrujllo et al.[1] who encapsulated β-carotene by hot homogenization at different amounts of polysorbate 80. The average size of particles was 570–780 nm, whereas a comparable amount of emulsifier and fat could form smaller particles (200 nm). They also reported that these SLNs could protect β-carotene and enhance its digestibility and bioaccessibility. SLNs based on tripalmitin and a mixture of tripalmitin and tricaprylin were also formulated by Schröder et al.[5] which were used as a Pickering emulsion stabilizer.
Advances in colloidal dispersions: A review
Published in Journal of Dispersion Science and Technology, 2020
Cang Huynh Mai, Tung Thanh Diep, Thuy T. T. Le, Viet Nguyen
Solid lipid nanoparticles (SLNs) are submicron colloidal carriers ranging from 50 to 1000 nm which are invented at the beginning of the 1990s as an alternative system of traditional colloidal drug carriers.[107–109] With more than three developing decades, the studies of SLNs have been dominating in the field of drug delivery. In theory, SLNs combine the advantages of lipid emulsion systems and polymeric nanoparticles systems while overcoming their disadvantages. Being similar to traditional drug carriers, SLNs are also biodegradable and nontoxic but the usage of solid lipids instead of liquid oil brought many significant advantages such as higher stability in long term storage and lower mobility of drug molecules.[110] In fact, the solid state of the lipid had higher mass transfer resistance in compared to emulsified liquid droplets resulting in a better release control.[111] Moreover, high drug loading capacity and easy to scale up are major reasons for the increase of SLNs application in the pharmaceutical industry.[109] Normally, SLNs can be classified into three main types including: matrix (drug is dispersed evenly in the solid lipid), shell (drug is dispersed outside of solid lipid) and core (drug is dispersed on solid lipid matrix) (Figure 4B)
Preparation and characterization of solid lipid nanoparticles of furosemide using quality by design
Published in Particulate Science and Technology, 2018
Hasan Ali, Sandeep Kumar Singh
Today, pharmaceutical nanotechnology proposes a prospect to approach closer to the objective of delivering the therapeutic molecule at the target cell/tissue/organ, at the accurate time and in the lowest possible therapeutic concentration (Kumar and Randhawa 2013). A perfect nano drug carrier must possess some unique properties such as adequate drug-loading ability, environmental stability, site selectivity, safety, efficacy, modified release, simple and economic scale-up ability (Burgess 2006). The lack of safe polymers with regulatory approval and their high cost have limited the widespread application of polymeric nanoparticles to clinical medicine (Wagner et al. 2006; Emerich and Thanos 2007; Zhang et al. 2008). To surmount the aforesaid limitations of polymeric nanoparticles, lipids have been employed as a nanoparticulate drug carrier of choice in general and for a lipophilic therapeutic agent in particular (Müller, Radtke, and Wissing 2002; Souto et al. 2004). These lipid nanoparticles are known as solid lipid nanoparticles (SLNs), a smart novel nano drug delivery carrier, which is attracting wide attention of pharmaceutical scientists. SLN is a colloidal drug carrier system, very much like nanoemulsions, where they are solidified and differing in lipid nature (Mehnert and Mader 2001). The liquid oils used in emulsions are replaced by lipids in SLN, which are solid at room temperature. It contains high melting, long- and medium-chained fatty acids, glycerides (mono, di and tri) or waxes of natural, synthetic and semisynthetic origin. The SLNs are stabilized by the natural and/or synthetic, biocompatible and biodegradable surfactant(s) (nonionic or ionic) (Mehnert and Mader 2001; Blasi et al. 2011; Ghadiri et al. 2012). The important advantage of SLNs as nano drug delivery systems is because the base materials used are physiologically related ingredients; additionally, these excipients fall under generally recognized as safe (GRAS) category for oral consumption, which reduces the risk of acute or chronic toxicity associated with pharmaceutical excipients (Vaghasiya, Kumar, and Sawant 2013). Apart from this, SLNs possess some other advantages like modulated drug delivery, enhancement of bioavailability of entrapped drug(s) via modification of dissolution rate and/or improvement of tissue distribution and targeting of drugs via surface modification (Goppert and Muller 2005; Venishetty et al. 2012; Huang et al. 2013; Yuan et al. 2013). Hence, SLN, as a colloidal drug carrier, has achieved significant attention as an alternating nano drug carrier relative to other colloidal systems (Mehnert and Mader 2001; Kumar and Randhawa 2013).